2Xideas AG Has $4.29 Million Stake in Hologic, Inc. $HOLX

2Xideas AG cut its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 9.5% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 63,554 shares of the medical equipment provider’s stock after selling 6,664 shares during the quarter. 2Xideas AG’s holdings in Hologic were worth $4,289,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in HOLX. Invesco Ltd. raised its position in shares of Hologic by 72.5% during the second quarter. Invesco Ltd. now owns 8,340,785 shares of the medical equipment provider’s stock worth $543,486,000 after purchasing an additional 3,505,828 shares during the period. Becker Capital Management Inc. increased its holdings in Hologic by 20.0% during the third quarter. Becker Capital Management Inc. now owns 81,755 shares of the medical equipment provider’s stock worth $5,518,000 after buying an additional 13,610 shares during the last quarter. Illinois Municipal Retirement Fund raised its stake in shares of Hologic by 20.4% in the third quarter. Illinois Municipal Retirement Fund now owns 172,294 shares of the medical equipment provider’s stock valued at $11,628,000 after buying an additional 29,143 shares during the period. Readystate Asset Management LP purchased a new stake in shares of Hologic during the 3rd quarter valued at approximately $4,161,000. Finally, Natixis Advisors LLC grew its stake in Hologic by 23.4% in the 3rd quarter. Natixis Advisors LLC now owns 437,338 shares of the medical equipment provider’s stock valued at $29,516,000 after buying an additional 82,894 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on HOLX shares. Weiss Ratings reissued a “hold (c)” rating on shares of Hologic in a report on Wednesday, January 28th. BNP Paribas Exane cut shares of Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 price objective for the company. in a research note on Friday, November 21st. Argus cut shares of Hologic from a “buy” rating to a “hold” rating in a research note on Monday, January 12th. Finally, Evercore downgraded shares of Hologic from an “outperform” rating to an “in-line” rating and cut their price target for the company from $79.00 to $78.00 in a report on Monday, January 5th. Two equities research analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $78.42.

Hologic Stock Performance

HOLX opened at $75.12 on Friday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.32 and a current ratio of 4.04. The stock has a market capitalization of $16.77 billion, a price-to-earnings ratio of 31.30, a PEG ratio of 2.24 and a beta of 0.73. The company has a fifty day moving average of $75.13 and a 200 day moving average of $72.64. Hologic, Inc. has a fifty-two week low of $51.90 and a fifty-two week high of $75.75.

Hologic (NASDAQ:HOLX) last posted its earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share for the quarter, missing analysts’ consensus estimates of $1.09 by ($0.05). Hologic had a return on equity of 19.58% and a net margin of 13.18%.The business had revenue of $1.05 billion during the quarter, compared to the consensus estimate of $1.07 billion. During the same quarter last year, the firm earned $0.87 earnings per share. The business’s quarterly revenue was up 2.5% on a year-over-year basis. As a group, sell-side analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Hologic Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.